These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 35908117

  • 1. Association of Genetic Polymorphisms in Kawasaki Disease with the Response to Intravenous Immunoglobulin Therapy.
    Sapountzi E, Fidani L, Giannopoulos A, Galli-Tsinopoulou A.
    Pediatr Cardiol; 2023 Jan; 44(1):1-12. PubMed ID: 35908117
    [Abstract] [Full Text] [Related]

  • 2. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
    Amano Y, Akazawa Y, Yasuda J, Yoshino K, Kojima K, Kobayashi N, Matsuzaki S, Nagasaki M, Kawai Y, Minegishi N, Ishida N, Motoki N, Hachiya A, Nakazawa Y, Yamamoto M, Koike K, Takeshita T.
    Pediatr Rheumatol Online J; 2019 Jul 03; 17(1):34. PubMed ID: 31269967
    [Abstract] [Full Text] [Related]

  • 3. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
    Chang LS, Lo MH, Li SC, Yang MY, Hsieh KS, Kuo HC.
    Oncotarget; 2017 Jan 10; 8(2):2044-2052. PubMed ID: 27893416
    [Abstract] [Full Text] [Related]

  • 4. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, Mossberg M, Kucera F, Tulloh R, Standing JF, Swallow V, McCormack R, Herberg J, Levin M, Wan M, Klein N, Connon R, Walker AS, Brogan P.
    Trials; 2023 Jan 26; 24(1):60. PubMed ID: 36703139
    [Abstract] [Full Text] [Related]

  • 5. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr 26; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

  • 6. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S.
    Ther Apher Dial; 2015 Apr 26; 19(2):171-7. PubMed ID: 25257673
    [Abstract] [Full Text] [Related]

  • 7. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Apr 26; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 8. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
    Zheng X, Li J, Yue P, Liu L, Li J, Zhou K, Hua Y, Li Y.
    PLoS One; 2021 Apr 26; 16(3):e0248812. PubMed ID: 33764989
    [Abstract] [Full Text] [Related]

  • 9. Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients.
    Wang Z, Xu Y, Zhou H, Wang Y, Li W, Lu Z, Jiang Z, Gu X, Zheng H, Zeng L, Huang P, Zhang L, Gu X.
    Cardiovasc Ther; 2020 Apr 26; 2020():3568608. PubMed ID: 32256707
    [Abstract] [Full Text] [Related]

  • 10. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
    J Huazhong Univ Sci Technolog Med Sci; 2005 Apr 26; 25(3):348-50, 370. PubMed ID: 16201293
    [Abstract] [Full Text] [Related]

  • 11. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
    Pediatr Neonatol; 2014 Oct 26; 55(5):387-92. PubMed ID: 24636168
    [Abstract] [Full Text] [Related]

  • 12. HMGB1 gene polymorphism is associated with coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
    Ahn JG, Bae Y, Shin D, Nam J, Kim KY, Kim DS.
    Rheumatology (Oxford); 2019 May 01; 58(5):770-775. PubMed ID: 30535242
    [Abstract] [Full Text] [Related]

  • 13. Recent advances in the treatment of Kawasaki disease.
    Weng KP, Ou SF, Lin CC, Hsieh KS.
    J Chin Med Assoc; 2011 Nov 01; 74(11):481-4. PubMed ID: 22100015
    [Abstract] [Full Text] [Related]

  • 14. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
    Kardiol Pol; 2017 Nov 01; 75(3):261-266. PubMed ID: 27995598
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.
    Tang B, Lo HH, Lei C, U KI, Hsiao WW, Guo X, Bai J, Wong VK, Law BY.
    Phytomedicine; 2020 Apr 15; 70():153208. PubMed ID: 32283413
    [Abstract] [Full Text] [Related]

  • 16. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM, Shulman ST.
    J Clin Pharm Ther; 2015 Dec 15; 40(6):620-5. PubMed ID: 26547265
    [Abstract] [Full Text] [Related]

  • 17. Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children.
    Mamtani M, Matsubara T, Shimizu C, Furukawa S, Akagi T, Onouchi Y, Hata A, Fujino A, He W, Ahuja SK, Burns JC.
    PLoS One; 2010 Jul 07; 5(7):e11458. PubMed ID: 20628649
    [Abstract] [Full Text] [Related]

  • 18. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 07; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 19. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
    [Abstract] [Full Text] [Related]

  • 20. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.
    Pediatr Cardiol; 2015 Aug 01; 36(6):1166-72. PubMed ID: 25812827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.